Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $44.00.

A number of research analysts recently weighed in on ASMB shares. Mizuho set a $45.00 target price on Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday, June 15th. Wall Street Zen downgraded Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Guggenheim reaffirmed a “buy” rating and set a $43.00 price objective on shares of Assembly Biosciences in a research report on Thursday, May 28th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a report on Monday, May 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Informed Momentum Co LLC increased its position in Assembly Biosciences by 1.6% during the 4th quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock worth $1,004,000 after buying an additional 451 shares during the period. ADAR1 Capital Management LLC lifted its holdings in shares of Assembly Biosciences by 4.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock worth $672,000 after buying an additional 800 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Assembly Biosciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock valued at $4,468,000 after acquiring an additional 1,212 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in shares of Assembly Biosciences by 4.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock valued at $1,095,000 after acquiring an additional 1,634 shares in the last quarter. Finally, Palumbo Wealth Management LLC grew its stake in shares of Assembly Biosciences by 7.2% in the fourth quarter. Palumbo Wealth Management LLC now owns 37,305 shares of the biopharmaceutical company’s stock valued at $1,269,000 after acquiring an additional 2,507 shares in the last quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Stock Performance

Assembly Biosciences stock opened at $25.06 on Tuesday. Assembly Biosciences has a 52 week low of $16.90 and a 52 week high of $39.71. The stock has a market capitalization of $398.20 million, a P/E ratio of -227.80 and a beta of 1.08. The stock has a 50-day simple moving average of $26.35 and a 200 day simple moving average of $27.89.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.11. The firm had revenue of $8.21 million for the quarter, compared to analyst estimates of $9.27 million. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%. Research analysts forecast that Assembly Biosciences will post 1.9 earnings per share for the current year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.